CRUK. 21 March 2016
Image shows false-coloured scanning electron micrograph of a single prostate cancer cell grown in culture
The National Institute for Health and Care Excellence (NICE) has approvedthe drug abiraterone for men with advanced prostate cancer, who have not yet had chemotherapy. The drug – developed by UK scientists – can delay the disease’s progression, help to prolong life, and provide a better quality of life with less fatigue and pain. It has been available across the UK for men after chemotherapy since 2012.
Under the discount, the NHS will pay for the first 10 months of treatment. For people who remain on treatment for more than 10 months, Janssen will cover the drug’s cost from the 11th month until the end of treatment.
Until now, the drug was only available to patients in England before chemotherapy through the Cancer Drugs Fund (CDF), and was the second most requested medicine on the fund. Today’s approval means that drug can now also been removed from the Fund – which is the process of being reformed – and paid for routinely by the NHS.
Read the full commentary here